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Abstract
Background: Metallo-β-lactamase-production among Gram-negative bacteria, including Pseudomonas aeruginosa, has become a challenge for treatment of infections
due to these resistant bacteria.
Objectives: The aim of the current study was to evaluate the metallo-β-lactamase-production and carriage of bla-VIM genes among carbapenem-resistant P. aeruginosa
isolated from burn wound infections.
Patients and Methods: A cross-sectional study was conducted from September 2014 to July 2015. One hundred and fifty P. aeruginosa isolates were recovered from
600 patients with burn wound infections treated at Imam-Musa-Kazem Hospital in Isfahan city, Iran. Carbapenem-resistant P. aeruginosa isolates were screened by disk
diffusion using CLSI guidelines. Metallo-β-lactamase-producing P. aeruginosa isolates were identified using an imipenem-EDTA double disk synergy test (EDTA-IMP DDST).
For detection of MBL genes including bla-VIM-1 and bla-VIM-2 , polymerase chain reaction (PCR) methods and sequencing were used.
Results: Among the 150 P. aeruginosa isolates, 144 (96%) were resistant to imipenem by the disk diffusion method, all of which were identified as metallo-β-lactamase-
producing P. aeruginosa isolates by EDTA-IMP DDST. Twenty-seven (18%) and 8 (5.5%) MBL-producing P. aeruginosa isolates harbored bla-VIM-1 and bla-VIM-2 genes, respectively.
Conclusions: Our findings showed a high occurrence of metallo-β-lactamase production among P. aeruginosa isolates in burn patient infections in our region. Also,
there are P. aeruginosa isolates carrying the bla-VIM-1 and bla-VIM-2 genes in Isfahan province.
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1. Background
Burn wounds are major public health problems all
over the world. Infection is one of the most complicated
issues in burn patients, because the skin, a barrier against
microbes, has been destroyed and the immunity agents
cannot reach the sites of infection. There is a correlation
between the severity of infection and the extent of the burn
(1). It has been estimated that about 75% of burn-related
mortality involves infections (2, 3). The rate of nosoco-
mial infections among patients hospitalized in burn units
is high, and P. aeruginosa has been documented as the
most prevalent isolated bacteria in these patients (4, 5).
Pseudomonas aeruginosa is characterized by an innate re-
sistance to multiple antimicrobial agent as well as by ac-
quired multidrug resistance ability. Due to multi-drug re-
sistant P. aeruginosa isolates, treating these patients’ burn
wound infections is challenging (6). Carbapenems are a
group of β-lactams that show resistance to hydrolysis by
extended-spectrum β-lactamases (ESBLs), so are used as
the drug of choice for treatment of infections caused by
ESBL-positive Gram negative bacteria (7). Broad spectrum
activity as well as these abilities have led to increased used
of carbapenems, especially imipenem, for treatment of
nosocomial infections (8). Unfortunately, the emergence
of metallo-β-lactamase (MBL), the enzyme that inactivates
carbapenems, has prevented the use of these antibiotics
(9). In a study conducted at Ghotbeddin Burn hospital in
Shiraz, 55 (20.4%) MBL-producing P. aeruginosa were identi-
fied among 270 P. aeruginosa isolated patients hospitalized
in the burn unit (1). MBLs are categorized as Ambler class B
(10). Theseβ-lactamase groups of enzymes have resistance
to all β-lactamase inhibitors, and due to the presence of
zinc ion in their active sites, are inactivated by chelating
agents such as ethylene diamine tetra acetic acid (EDTA)
(9). Metallo-β-lactamase-production is encoded by either
chromosomal genes or genes are inserted in mobile ge-
netic elements, which especially facilitate the spread of
these genes among Gram negative bacteria (9). Recently,
several new MBL codes such as VIM have been documented
in P. aeruginosa isolates (7). The three main clusters of VIM
MBL have been reported, including VIM-1, VIM-2, and VIM-7
(7), and the VIM type metallo-β-lactamase genes are shown
to encode by inserted cassettes in the mobile integrons (7,
11). The rate of the infections caused by P. aeruginosa in
the burn unit of Imam-Musa-Kazem hospital in Isfahan was
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high; therefore rapid identification of MBL-producing P.
aeruginosa strains is important.
2. Objectives
In the present study we determined the metallo-β-
lactamase-production and carriage of bla-VIM genes among
carbapenem-resistant P. aeruginosa isolates in burn pa-
tients in Isfahan Province.
3. Patients and Methods
3.1. Subjects
This cross-sectional study was conducted on 600
patients, who were hospitalized in the burn unit of
Imam-Musa-Kazem university Hospital in Isfahan between
September 2014 and July 2015.
3.2. Bacterial strains
For sampling, wound swabs were obtained from the
burn patients and P. aeruginosa was identified by standard
microbiological methods including Gram stains, culture
on mediums such as blood agar, MacConkey agar, triple
sugar iron agar (TSI), cetrimide agar (Merck, UK), oxidase
(Sigma, USA), catalase, oxidative/fermentative (OF), indole,
methyl red (MR), Voges-Proskauer (VP) tests (Merck, UK),
and growth at 42°C.
3.3. Screening of Carbapenem-Resistant and MBL Producing
Pseudomonas aeruginosa Isolates
The disk diffusion method was used according to the
clinical and laboratory standards institute (CLSI) guide-
lines for detection of carbapenem-resistant P. aeruginosa
isolates, and the imipenem (10µg) and meropenem (10µg)
disks were purchased from Mast, UK Company (12). A P.
aeruginosa standard strain (ATCC 27853) was used for qual-
ity control in susceptibility testing. Phenotypic screening
for MBL producers P. aeruginosa isolates was performed us-
ing an EDTA double disk synergy test (EDTA-IMP DDST) in
which imipenem resistant isolates selected by the disk dif-
fusion method were examined. Briefly, a colony of each P.
aeruginosa strain was suspended in Mueller-Hinton (MH)
broth to 106 CFU/mL. after being spread on an MH agar
plate with a cotton swab. Two commercial disks containing
10µg imipenem with (10µg/750µg) and without EDTA were
placed on the center of the plate at a distance of 25 mm
from each other, and were incubated at 37°C overnight. Af-
ter overnight incubation, the presence of a ≥ 7 mm syn-
ergistic inhibition zone around the IMP-EDTA disk in com-
parison to the IMP disk was interpreted as positive (13).
3.4. Polymerase Chain Reaction Detection of Genes for MBLs
DNA from each P. aeruginosa isolate was extracted by
the boiling method. Templates of the DNA were stored
at -20°C until PCR amplification was performed. MBL-
producing P. aeruginosa strains which were identified by a
DDST confirmatory test were amplified by the PCR method,
using bla-VIM-1 and bla-VIM-2 specific primers (Table 1) for am-
plification of 261 bp and 801 bp fragments, respectively (14).
Reactions were carried out using a thermo cycler
(Eppendorf master cycler®, MA) in the PCR conditions
previously described (14). For confirmation, some PCR
products were sent elsewhere for sequencing (Bioneer,
South Korea). The nucleotide sequences were analyzed
by the program Chromas Pro version1.7.5 Technelysium
(www.technelysium.com.au), and were aligned with Gen-
Bank to check the identity of each sequence against those
deposited in GenBank.
3.5. Ethical Considerations
Each patient’s demographic information was obtained
by a survey questionnaire, and a written informed consent
was received from all patients or their parents. The study
design, including its ethical aspects, was reviewed and ap-
proved by the ethics committee of Kashan University of
Medical Sciences (No. 4380).
3.6. Statistical Analysis
The statistical analysis of data was conducted using
SPSS software version 16 (SPSS, Inc.). Differences by the χ2
test were considered statistically significant if the P value
was less than 0.05 (P < 0.05).
4. Results
Of 600 burn patients, who had been hospitalized in the
burn unit of Imam-Musa-Kazem university hospital in Is-
fahan, a total of 150 P. aeruginosa isolates were recovered.
The patients with isolates included 69 (46.0%) females and
81 (54.0%) males, and their ages ranged between 1 and 72
years old (Table 2). Of the 150 P. aeruginosa isolates iden-
tified by standard biochemical tests, 144 (96.0%) and 144
(96.0%) showed resistance to imipenem and meropenem,
respectively, by the disk diffusion method. An EDTA-IMP
DDST phenotypic confirmatory test revealed that 100% of
the imipenem resistant P. aeruginosa isolates were metallo-
β-lactamase producing (Figure 1).
The finding of the PCR assays showed that of 144 MBL-
producing P. aeruginosa isolates, 27 (18%) and 8 (5.5%) were
positive for the bla-VIM-1 and bla-VIM-2 genes, respectively
(Figure 2). The nucleotide sequences of the PCR products
of the bla-VIM-1 and bla-VIM-2 genes were identical to those de-
posited in GenBank.
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Table 1. Primers Used for Polymerase Chain Reaction and Sequencing
Primer Target Gene Sequence (5’→3’) Amplification Product, bp
VIM-1 F blaVIM-1 AGT GGT GAG TAT CCG ACA G 261
VIM-1 R blaVIM-1 ATG AAA GTG CGT GGA GAC
VIM-2 F blaVIM-2 ATG TTC AAA CTT TTG AGT AAG 801
VIM-2 R blaVIM-2 CTA CTC AAC GAC TGA GCG
Table 2. Association Between Burn Patients’ Demographic Characteristics and blaVIM Genes Carriage Among Pseudomonas aeroginosa Isolates
Factor blaVIM-1 P Value blaVIM-2 P Value Total, No. (%)
Positive, No. (%) Negative, No. (%) Positive, No. (%) Negative, No. (%)
Sex
Male 20 (13.3) 61 (40.7) 0.374 4 (2.7) 77 (51.3) 0.449 81 (54.0)
Female 7 (4.7) 62 (41.3) 4 (2.7) 65 (43.3) 69 (46.0)
Age group, y
Less than 30 5 (3.3) 25 (16.7) 0.812 1 (0.7) 29 (19.3) 1 30 (20.0)
30 - 49 21 (14.0) 90 (60.0) 3 (2.0) 108 (72.0) 111 (74.0)
More than 50 1 (0.7) 8 (5.3) 4 (2.7) 5 (3.3) 9 (6.0)
Burn level (38.85± 7.58)
Equal and less than 35 7 (4.7) 24 (16.0) 0.041 3 (2.0) 28 (18.7) 0.032 31 (20.7)
More than 35 20 (13.3) 99 (66.0) 5 (3.3) 114 (76.0) 119 (79.3)
Burn cause
Fire and flame 13 (8.7) 49 (32.6) 0.161 4 (2.7) 58 (38.6) 0.212 62 (41.3)
Chemical 5 (3.3) 14 (9.4) 0 19 (12.7) 19 (12.7)
Boiled water and hot liquids 9 (6.0) 60 (40.0) 4 (2.7) 65 (43.3) 69 (46.0)
Figure 1. Metallo-β-Lactamase Producing Pseudomonas aeruginosa Isolates Identi-
fied By a Imipenem-EDTA Double Disk Synergy Test (EDTA-IMP DDST) Phenotypic Con-
firmatory Test
5. Discussion
Pseudomonas aeruginosa is documented as one of the
most frequently isolated bacteria in nosocomial infec-
tions, especially in burn units (3). Severe antimicrobial
resistance in this bacterium has complicated the treat-
ment of infections caused by drug-resistant P. aeruginosa
strains among burn patients (15). Recently, the increase
of carbapenem resistance in P. aeruginosa has been docu-
mented all over the world due to metallo-β-lactamase pro-
duction, including the VIM type (16). This study revealed
that the resistance rates to imipenem and meropenem
were very high (96%). Farajzadeh Sheikh et al. (15) reported
an imipenem resistance rate of 58.7% among P. aeruginosa
isolates in Ahwaz, which was lower than our resistance
rate. However, Anvarinejad and colleagues’ (1) study, also
conducted in Ahwaz, was in agreement with our study:
98.1% of MBL-producing P. aeruginosa strains, which were
isolated from hospitalized patients in a burn unit showed
resistance to imipenem. Another report, in contrast with
our study, found a resistance rate of 21% to imipenem
among P. aeruginosa samples from burn patients in Kur-
distan (3). As carbapenems, including imipenem, are the
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Figure 2. Amplification of blaVIM-1 and blaVIM-2 Genes in Imipenem Resistant MBL Positive Pseudomonas aeruginosa Isolates
M lanes, 100-bp DNA ladder as the molecular size marker; A, lane 1, positive control; lanes 2 - 4, blaVIM-1 positive Pseudomonas aeruginosa isolates; lane 5, negative control; B, lane
1, positive control; lane 2, blaVIM-2 positive Pseudomonas aeruginosa isolate; lane 3, negative control.
drugs of choice for treatment of infections caused by MDR-
P. aeruginosa strains, this result in particularly alarming for
burn patients with immune-compromised defenses. The
high resistance rates to carbapenems may be relatively im-
precise because they were not confirmed by confirmatory
tests such as an E-test. The difference in resistance rates
to imipenem in P. aeruginosa isolates from burn patients
in Ahwaz, Isfahan, and Kurdistan could be due to frequent
use of this antibiotic and the occurrence of high selective
pressure in Ahwaz and Isfahan, and fewer patients’ access
to antibiotics due to economic problems in Kurdistan.
MBL-producing P. aeruginosa have been isolated from
hospitalized patients increasingly, and isolates that pro-
duce these families of enzymes have been documented as
one cause of prolonged nosocomial infections (17). Here
we showed that all imipenem-resistant P. aeruginosa iso-
lates had the ability of MBL-production. In Kurdistan
and Ahwaz 22% and 19.5% of P. aeruginosa isolates among
burn patients were identified as MBL-producing isolates
(3). In a study conducted by Farajzadeh Sheikh et al. (15)
in Ahwaz among P. aeruginosa isolates in burn and non-
burn patients, all of the imipenem-resistant isolates were
MBL E-test positive, which correlates with our results, al-
though it would be better if the MBL-production among
our imipenem resistant P. aeruginosa isolates were con-
firmed by an MBL E-test as well. The EDTA-IMP DDST test
and sodium mercaptoacetic acid (SMA)-IMP DDST revealed
that 98.1% of imipenem-resistant P. aeruginosa and 78.9%
of P. aeruginosa isolates were positive for production of
metallo-β-lactamase enzymes in Brazil and Japan, respec-
tively (8, 14). This finding shows that the prevalence of car-
bapenemases among nosocomial isolates of P. aeruginosa
is high, especially in burn units.
It has been estimated that more than 40% of imipenem
resistance in P. aeruginosa (IRPA) is due to MBL produc-
tion, although enzyme types vary in different regions (18,
19). In the present study, 18% and 5.5% of MBL positive iso-
lates were VIM-1 and VIM-2 MBL types, respectively. Sim-
ilar to our finding, 19.3% of MBL-producing P. aeruginosa
isolates in burn patients in Ahwaz were positive for bla-VIM
genes (7). In a study in Brazil, 19% of IRPA isolates which
were MBL-positive were shown to carry bla-VIM-2, whereas
bla-VIM-1 was not detected among them (8). The fact that
the bla-VIM-2 gene was detected in 48.8% of IRPA clinical iso-
lates in Romania (20) shows that MBL type enzymes can
vary geographically. Another interesting finding was that
the remaining 109 IRPA isolates, which were MBL positive
by a phenotypic test, proved to be negative for bla-VIM-1 and
bla-VIM-2 genes. The presence of other types of MBL genes
could be the reason.
Overall, the findings of the current study showed that
the resistance rate to carbapenems, as the last-resort ther-
apy in infections due to MDR P. aeruginosa strains among
burn patients, is high. Therefore, in these patients a reg-
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ular surveillance program for controlling infection and in
vitro testing of antibiotics before empiric treatment could
be helpful to control MDR-Pseudomonas aeruginosa infec-
tions in the burn units. Also, a high occurrence of MBL pro-
duction among imipenem-resistant P. aeruginosa isolates
in burn patients was seen. Further studies using more ac-
curate confirmatory tests in our region are recommended.
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